Lercastad (Lercanidipine Hydrochloride)

Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth‑muscle cells. By blocking calcium entry, it induces relaxation of arterial smooth muscle, producing vasodilation and a decrease in peripheral vascular resistance, which leads to a reduction in systemic blood pressure without markedly affecting heart rate.

The dosage of Lercastad is individualized by the prescribing healthcare professional based on the patient’s blood pressure response, age, and renal or hepatic function. The prescriber determines the appropriate starting dose and any subsequent adjustments, and patients should follow the prescribed regimen exactly.

Safety of lercanidipine in pregnancy and lactation has not been established. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Lercastad. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Lercastad belongs to the dihydropyridine calcium‑channel blocker class, offering potent vasodilatory effects with a long half‑life that allows once‑daily dosing. Compared with beta‑blockers or ACE inhibitors, it primarily reduces peripheral resistance and may be preferred when heart rate control is not required, but combination therapy is common for optimal blood pressure control.

Lercastad should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keeping the product in a dry, well‑ventilated area helps maintain its stability and potency throughout its shelf life.

Lercastad is taken orally, usually as a whole tablet swallowed with a glass of water. It is typically administered once daily, with or without food, unless otherwise directed by the prescribing clinician. Patients should not crush, chew, or split the tablet unless specifically instructed.

Serious adverse events, although rare, include severe hypotension, angio‑edema, myocardial infarction, and hepatotoxicity. Patients should seek immediate medical attention if they experience sudden dizziness, fainting, swelling of the face or throat, chest pain, or signs of liver dysfunction while on therapy.

Lercastad is contraindicated in patients with known hypersensitivity to lercanidipine or any component of the formulation. Caution is advised for individuals with severe hepatic impairment, uncontrolled heart failure, or those taking strong CYP3A4 inhibitors, as these conditions may increase the risk of adverse effects.